CymaBay Therapeutics Q3 EPS $(0.32) Misses $(0.30) Estimate
Portfolio Pulse from bharat@benzinga.com
CymaBay Therapeutics reported Q3 losses of $(0.32) per share, missing the analyst consensus estimate of $(0.30) by 6.67%. This represents a 14.29% increase in losses compared to the same period last year.
November 07, 2023 | 9:13 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CymaBay Therapeutics' Q3 earnings per share of $(0.32) missed the consensus estimate, representing a 14.29% increase in losses YoY.
CymaBay Therapeutics reported a larger than expected loss for Q3, missing analyst estimates. This is likely to negatively impact investor sentiment and could lead to a short-term decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100